vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and H2O AMERICA (HTO). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $199.4M, roughly 1.4× H2O AMERICA). H2O AMERICA runs the higher net margin — 8.1% vs -45.7%, a 53.8% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 1.5%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 15.3%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
H2O Wireless is a United States-based prepaid cell phone service, that utilizes the AT&T network. It is a brand of the mobile virtual network operator (MVNO) Locus Telecommunications, a subsidiary of Telrite Holdings, Inc., since 2019. Locus was formerly a subsidiary of KDDI America corporation, starting in 2010. H2O Wireless is primarily advertised as a non-restrictive phone service for customers to bring or buy unlocked smartphones, although AT&T contract/locked phones may be accepted as well.
GH vs HTO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $199.4M |
| Net Profit | $-128.5M | $16.2M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 16.6% |
| Net Margin | -45.7% | 8.1% |
| Revenue YoY | 39.4% | 1.5% |
| Net Profit YoY | -15.8% | -29.2% |
| EPS (diluted) | $-1.01 | $0.45 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $199.4M | ||
| Q3 25 | $265.2M | $243.5M | ||
| Q2 25 | $232.1M | $197.8M | ||
| Q1 25 | $203.5M | $164.9M | ||
| Q4 24 | $201.8M | $196.5M | ||
| Q3 24 | $191.5M | $216.7M | ||
| Q2 24 | $177.2M | $173.1M | ||
| Q1 24 | $168.5M | $150.0M |
| Q4 25 | $-128.5M | $16.2M | ||
| Q3 25 | $-92.7M | $45.1M | ||
| Q2 25 | $-99.9M | $24.7M | ||
| Q1 25 | $-95.2M | $16.6M | ||
| Q4 24 | $-111.0M | $22.9M | ||
| Q3 24 | $-107.8M | $38.7M | ||
| Q2 24 | $-102.6M | $20.7M | ||
| Q1 24 | $-115.0M | $11.7M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 16.6% | ||
| Q3 25 | -37.3% | 26.5% | ||
| Q2 25 | -45.9% | 22.2% | ||
| Q1 25 | -54.6% | 21.8% | ||
| Q4 24 | -62.4% | 22.2% | ||
| Q3 24 | -61.3% | 26.9% | ||
| Q2 24 | -56.8% | 23.4% | ||
| Q1 24 | -59.2% | 18.6% |
| Q4 25 | -45.7% | 8.1% | ||
| Q3 25 | -35.0% | 18.5% | ||
| Q2 25 | -43.0% | 12.5% | ||
| Q1 25 | -46.8% | 10.0% | ||
| Q4 24 | -55.0% | 11.7% | ||
| Q3 24 | -56.3% | 17.8% | ||
| Q2 24 | -57.9% | 12.0% | ||
| Q1 24 | -68.2% | 7.8% |
| Q4 25 | $-1.01 | $0.45 | ||
| Q3 25 | $-0.74 | $1.27 | ||
| Q2 25 | $-0.80 | $0.71 | ||
| Q1 25 | $-0.77 | $0.49 | ||
| Q4 24 | $-0.90 | $0.70 | ||
| Q3 24 | $-0.88 | $1.17 | ||
| Q2 24 | $-0.84 | $0.64 | ||
| Q1 24 | $-0.94 | $0.36 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $20.7M |
| Total DebtLower is stronger | $1.5B | $1.9B |
| Stockholders' EquityBook value | $-99.3M | $1.5B |
| Total Assets | $2.0B | $5.1B |
| Debt / EquityLower = less leverage | — | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $20.7M | ||
| Q3 25 | $580.0M | $11.3M | ||
| Q2 25 | $629.1M | $19.8M | ||
| Q1 25 | $698.6M | $23.7M | ||
| Q4 24 | $525.5M | $11.1M | ||
| Q3 24 | $585.0M | $4.0M | ||
| Q2 24 | $933.7M | $22.8M | ||
| Q1 24 | $1.0B | $4.5M |
| Q4 25 | $1.5B | $1.9B | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | $1.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $1.5B | ||
| Q3 25 | $-354.5M | $1.5B | ||
| Q2 25 | $-305.5M | $1.5B | ||
| Q1 25 | $-250.8M | $1.4B | ||
| Q4 24 | $-139.6M | $1.4B | ||
| Q3 24 | $-60.1M | $1.3B | ||
| Q2 24 | $-1.6M | $1.3B | ||
| Q1 24 | $68.3M | $1.2B |
| Q4 25 | $2.0B | $5.1B | ||
| Q3 25 | $1.3B | $5.0B | ||
| Q2 25 | $1.3B | $4.8B | ||
| Q1 25 | $1.3B | $4.7B | ||
| Q4 24 | $1.5B | $4.7B | ||
| Q3 24 | $1.5B | $4.6B | ||
| Q2 24 | $1.6B | $4.4B | ||
| Q1 24 | $1.7B | $4.4B |
| Q4 25 | — | 1.23× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.26× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $63.5M |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | 3.92× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $63.5M | ||
| Q3 25 | $-35.4M | $77.3M | ||
| Q2 25 | $-60.3M | $60.8M | ||
| Q1 25 | $-62.7M | $43.2M | ||
| Q4 24 | $-64.5M | $41.5M | ||
| Q3 24 | $-51.1M | $53.5M | ||
| Q2 24 | $-94.0M | $49.3M | ||
| Q1 24 | $-30.3M | $51.2M |
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | — | ||
| Q2 25 | $-65.9M | — | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | — | ||
| Q1 24 | $-37.2M | — |
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | — | ||
| Q2 25 | -28.4% | — | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | — | ||
| Q1 24 | -22.1% | — |
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.9% | — | ||
| Q1 24 | 4.1% | — |
| Q4 25 | — | 3.92× | ||
| Q3 25 | — | 1.71× | ||
| Q2 25 | — | 2.47× | ||
| Q1 25 | — | 2.61× | ||
| Q4 24 | — | 1.81× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | — | 2.38× | ||
| Q1 24 | — | 4.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
HTO
| Water Utility Services | $191.0M | 96% |
| Other | $8.4M | 4% |
